VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff

A Phase 3a, observer-blind, randomized, controlled study to evaluate the safety of an investigational varicella vaccine compared with Varivax, administered as a first dose to healthy children 12 to 15 months of age.

A Phase 3a, observer-blind, randomized, controlled study to demonstrate lot-to-lot consistency and evaluate the immunogenicity and safety of an investigational varicella vaccine compared with Varivax, administered as a first dose to healthy children 12 to 15 months of age.

A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared with Varivax, When Given as a Second Dose to Healthy Children, 3 Months after the Administration of a First Dose at 12 to 15 Months of age

A Phase 3a, open-label, randomized, controlled study to evaluate the immunogenicity and safety of intramuscular administration of an investigational varicella vaccine and Priorix compared with subcutaneous administration of Varivax and Priorix, when given as a first dose to healthy children 12 to 15 months of age